Journal
VACCINE
Volume 26, Issue 52, Pages 6883-6893Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.09.084
Keywords
HIV-1; Vaccine; Therapeutic immunization
Categories
Funding
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Child Health and Human Development through the International Maternal Pediatric Adolescent AIDS Clinical Trials Network [U01-AI-068632, N01-HD-33345]
- National Center for Research Resources
- IMPAACT network laboratories [U01 Al-069516]
- University of Massachusetts Center for AIDS Research Clinical Investigation and Molecular Virology Cores [Al-042845]
- NIH [HD-001489, Al-032391]
Ask authors/readers for more resources
A trial to evaluate the safety and immunogenicity of recombinant modified vaccinia Ankara (MVA) and fowlfox (FP) vectors expressing Multiple HIV-1 proteins was conducted in twenty HIV-1 infected youth with suppressed viral replication on HAART. The MVA and FP-based multigene HIV-1 vaccines were safe and well tolerated. Increased frequencies of HIV-1 specific CD4+ proliferative responses and cytokine secreting cells were detected following immunization. Increased frequencies and breadth of HIV-1 specific CE8 T-cell responses were also detected. Plasma HIV-1-specific antibody levels and neutralizing activity were unchanged following vaccination. Poxvirus-based vaccines may merit further study in therapeutic vaccine protocols. (C) 2008 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
